Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06787989 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 22, 2025 (before its estimated August 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR T cells in patients with refractory ITP associated with autoimmune disease.
Trial Details
NCT Number NCT06787989
Lead Sponsor iCell Gene Therapeutics
Collaborators: iCell ImmunityX（Hangzhou）Co., Ltd.
Conditions
(from sponsor)		 Refractory Immune Cytopenia
Related terms Purpura, Thrombocytopenic, Idiopathic
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov